Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

Kushner BH, LaQuaglia MP, Modak S, Wolden SL, Basu EM, Roberts SS, Kramer K, Yataghene K, Cheung IY, Cheung NV.

Oncotarget. 2017 Aug 24;8(56):95293-95302. doi: 10.18632/oncotarget.20513. eCollection 2017 Nov 10.

2.

Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.

Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R.

Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23.

3.

Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.

Modak S, Kushner BH, Basu E, Roberts SS, Cheung NK.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26448. Epub 2017 Jan 23.

PMID:
28111925
4.

Molecular profiling of childhood cancer: Biomarkers and novel therapies.

Saletta F, Wadham C, Ziegler DS, Marshall GM, Haber M, McCowage G, Norris MD, Byrne JA.

BBA Clin. 2014 Jun 28;1:59-77. doi: 10.1016/j.bbacli.2014.06.003. eCollection 2014 Jun. Review.

5.

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K, Cheung NK.

Oncotarget. 2016 Jan 26;7(4):4155-66. doi: 10.18632/oncotarget.6393.

6.

Primary Multiple Pulmonary Primitive Neuroectodermal Tumor: Case Report and Literature Review.

Dong M, Liu J, Song Z, Li X, Shi T, Wang D, Ren D, Chen J.

Medicine (Baltimore). 2015 Jul;94(27):e1136. doi: 10.1097/MD.0000000000001136.

7.

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Kramer K, Modak S, Yataghene K, Cheung NK.

Oncoimmunology. 2015 May 22;4(7):e1016704. eCollection 2015 Jul.

8.

Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.

Kushner BH, Modak S, Kramer K, LaQuaglia MP, Yataghene K, Basu EM, Roberts SS, Cheung NK.

Cancer. 2014 Jul 1;120(13):2050-9. doi: 10.1002/cncr.28687. Epub 2014 Apr 1.

9.

Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.

Kushner BH, Cheung IY, Modak S, Kramer K, Ragupathi G, Cheung NK.

Clin Cancer Res. 2014 Mar 1;20(5):1375-82. doi: 10.1158/1078-0432.CCR-13-1012. Epub 2014 Feb 11.

10.

A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.

Venkatramani R, Malogolowkin M, Davidson TB, May W, Sposto R, Mascarenhas L.

PLoS One. 2013 Jul 22;8(7):e68416. doi: 10.1371/journal.pone.0068416. Print 2013.

11.

Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.

Grill J, Geoerger B, Gesner L, Perek D, Leblond P, Cañete A, Aerts I, Madero L, de Toledo Codina JS, Verlooy J, Estlin E, Cisar L, Breazna A, Dorman A, Bailey S, Nicolin G, Grundy RG, Hargrave D; European Consortium Innovative Therapies for Children with Cancer (ITCC) and the European Society for Paediatric Oncology (SIOPE) brain tumor group.

Neuro Oncol. 2013 Sep;15(9):1236-43. doi: 10.1093/neuonc/not097. Epub 2013 Jul 14.

12.

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.

Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2013 May;60(5):783-90. doi: 10.1002/pbc.24368. Epub 2013 Jan 17.

13.

ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma.

Huynh T, Norris MD, Haber M, Henderson MJ.

Front Oncol. 2012 Dec 19;2:178. doi: 10.3389/fonc.2012.00178. eCollection 2012.

14.

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, Modak S.

J Clin Oncol. 2012 Sep 10;30(26):3264-70. doi: 10.1200/JCO.2011.41.3807. Epub 2012 Aug 6.

15.

Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.

Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, Kretschmar C, Cohn SL.

J Clin Oncol. 2011 Jan 10;29(2):208-13. doi: 10.1200/JCO.2010.31.7107. Epub 2010 Nov 29.

16.

Targeted Therapy of Ewing's Sarcoma.

Subbiah V, Anderson P.

Sarcoma. 2011;2011:686985. doi: 10.1155/2011/686985. Epub 2010 Oct 31.

17.

Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.

Cai W, Maldonado NV, Cui W, Harutyunyan N, Ji L, Sposto R, Reynolds CP, Keshelava N.

Br J Cancer. 2010 Oct 26;103(9):1369-79. doi: 10.1038/sj.bjc.6605927. Epub 2010 Oct 5.

18.

Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.

Mascarenhas L, Lyden ER, Breitfeld PP, Walterhouse DO, Donaldson SS, Paidas CN, Parham DM, Anderson JR, Meyer WH, Hawkins DS.

J Clin Oncol. 2010 Oct 20;28(30):4658-63. doi: 10.1200/JCO.2010.29.7390. Epub 2010 Sep 13. Erratum in: J Clin Oncol. 2011 Apr 1;29(10):1394. J Clin Oncol. 2015 Jul 20;33(21):2412.

19.

Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.

Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC.

Pediatr Blood Cancer. 2010 Apr;54(4):538-45. doi: 10.1002/pbc.22407.

20.

Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma.

Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P, Humm JL, Xu H, Wolden SL, Souweidane MM, Larson SM, Cheung NK.

J Neurooncol. 2010 May;97(3):409-18. doi: 10.1007/s11060-009-0038-7. Epub 2009 Nov 5.

Supplemental Content

Support Center